Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: in vitro and in vivo considerations.
OBJECTIVE
Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. In inflammatory bowel disease (IBD), where major modifications of the intestinal microflora have been reported, there is an increasing interest in modulating the flora with probiotic products. This work addresses the anti-inflammatory potential of Lactibiane Tolérance, a probiotic dietary supplement (mixture of four strains) using in vitro and in vivo approaches.


METHODS
Comparison of the four individual strains and the commercial product reconstituted from them was conducted by in vitro tests (cytokine release after 24h stimulation of human peripheral blood mononuclear cells (PBMC)). The potential immunomodulatory characteristics of Lactibiane Tolérance were determined in vivo in an acute mice model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Assessment of colitis included blinded histological and macroscopic scores.


RESULTS
We showed that Lactibiane Tolérance has anti-inflammatory properties in vitro by stimulating IL-10 production and in vivo by conferring a significant protective effect in the TNBS-induced colitis model (more than 50% decrease of colitis symptoms, P<0.01).


CONCLUSIONS
These results demonstrate that a probiotic dietary supplement, Lactibiane Tolérance, can significantly prevent the initial injury of TNBS and could stimulate the initiation of clinical trials in IBD.
Drouault-Holowacz
Sophie
S
PiLeJe, 37 Quai de Grenella, 75738 Paris Cedex 15, France. s.holowacz@pileje.com
Foligné
Benoît
B
Dennin
Véronique
V
Goudercourt
Denise
D
Terpend
Kathleen
K
Burckel
André
A
Pot
Bruno
B
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001644:Bifidobacterium / Q000254:growth & development / Q000502:physiology; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D016207:Cytokines / Q000096:biosynthesis; D019587:Dietary Supplements; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D007778:Lactobacillus / Q000254:growth & development / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics; D011897:Random Allocation; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D014302:Trinitrobenzenesulfonic Acid